-

11:11:30 AM

HALO Stock News

HALO - Halozyme Therapeutics Inc.

01/10/22 8:00 AM

Nasdaq : HALO

HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2022 financial guidance and commented on its outlook for the upcoming year. "Halozyme had another strong year of financial performance in 2021 with record revenues and profitability driven by strong

RHEA-AI

positive

01/04/22 8:00 AM

Nasdaq : HALO

conferences

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 40 th Annual J.P. Morgan Health Care Conference on Monday, January 10, 2022 at 7:30 a.m. PT / 10:30 a.m. ET.

RHEA-AI

neutral

12/13/21 4:05 PM

Nasdaq : HALO

management

HALOZYME APPOINTS NEW GENERAL COUNSEL

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who

RHEA-AI

neutral

12/09/21 4:01 PM

Nasdaq : HALO

buyback

HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its Board of Directors has approved a new share repurchase program effective immediately, which authorizes the Company to purchase up to $750 million of the Company's outstanding common stock

RHEA-AI

neutral

12/01/21 2:21 PM

Nasdaq : HALO

fda approval

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis ® (carfilzomib) and

RHEA-AI

very positive

11/18/21 9:00 AM

Nasdaq : HALO

conferences

Halozyme to Present at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences:33rd Annual Piper Sandler Virtual Healthcare Conference , Elaine Sun, senior vice president and chief financial officer, will represent

RHEA-AI

neutral

11/02/21 4:01 PM

Nasdaq : HALO

Halozyme Reports Third Quarter 2021 Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2021 and provided an update on its recent corporate activities and outlook. "Our strong 2021 performance continued in the third quarter

RHEA-AI

positive

10/19/21 4:05 PM

Nasdaq : HALO

conferencesearnings

Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same

RHEA-AI

neutral

09/15/21 4:05 PM

Nasdaq : HALO

conferences

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 1:20 p.m. Eastern

RHEA-AI

neutral

08/26/21 9:00 AM

Nasdaq : HALO

conferences

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present at the Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:40 a.m. Eastern Time / 7:40 a.m.

RHEA-AI

neutral

HALO Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.halozyme.com
CeoHelen Torley
Security nameHalozyme Therapeutics Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees136
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address11388 Sorrento Valley Rd
StateCalifornia
CitySan Diego
Zip92121-1345
CountryUS
Phone18587948889

HALO Description:

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.